Ovarian cancer - paclitaxel (review)

The review and re-appraisal of the use of paclitaxel in the treatment of ovarian cancer has resulted in a change in the guidance. Specifically there has been: a change in recommendations on the alternative treatments offered for first-line therapy (section 1.1); an emphasis that women should b ...

Read the complete summary

The review and re-appraisal of the use of paclitaxel in the treatment of ovarian cancer has resulted in a change in the guidance. Specifically there has been:

• a change in recommendations on the alternative treatments offered for first-line therapy (section 1.1);
• an emphasis that women should be involved in making choices about their treatment (section 1.2);
• clarification of the distinction between re-challenge and second-line treatment (section 1.3);

There has been no significant change in the guidance on the use of
paclitaxel in the second-line (or subsequent) treatment (section 1.4).

hide